Investors continued to buy risk assets on Wednesday, including growth stocks, tech stocks, and cryptocurrencies, following a sharp move higher on Tuesday. And as highly correlated assets, it's no surprise they're all up in unison today.The move in crypto is largely because of macroeconomic news, ...

ServiceNow reports first-quarter revenue of $3.09 billion, beating the consensus estimate of $3.08 billion. ServiceNow reports first-quarter adjusted earnings of $4.04 per share, beating analyst estimates of $3.84 per share. Feel unsure about the market's next move?

Truist cuts price target to $590 due to tariff impact but keeps Buy rating. Intuitive Surgical ends Q1 2025 with $9.1 billion in cash and no debt. China's new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for Matt Maley. Get the next trade alert free.

Southwest Airlines said Wednesday that it will reduce its capacity in the second half of the year, as more signs point to weaker domestic bookings this year. The airline said it expects unit revenue to be flat to down as much as 4% in the second quarter from a year earlier.

Aptose Announces Auditor Not Standing for ...

Not for Distribution to U.S. Newswire Services or for Dissemination in the United States of America.

In the current market session, James Hardie Industries Inc. JHX price is at $23.60, after a 4.89% increase. However, over the past month, the stock decreased by 1.43%, and in the past year, by 32.73%.

New York City, April 23, 2025 ( GLOBE NEWSWIRE ) -- In today's fast-paced world, more and more people are waking up feeling exhausted, bloated, and disconnected from their bodies. Despite clean eating, daily workouts, and drinking plenty of water, weight just won't budge, and energy crashes ...

Ensysce stock trades up with 26.79 million volume, far exceeding the 81.23K average. PF614-MPAR showed reduced oxycodone release in overdose scenarios during trials. Don't face extreme market conditions unprepared.

ROCKVILLE, Md., April 23, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. ( Nasdaq: SUPN ) , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases, today announced that the Company expects to report ...